S&P 500
(0.32%) 5 116.17 points
Dow Jones
(0.38%) 38 386 points
Nasdaq
(0.35%) 15 983 points
Oil
(-0.04%) $82.60
Gas
(0.84%) $2.05
Gold
(-0.55%) $2 344.80
Silver
(-1.03%) $27.38
Platinum
(-0.29%) $958.70
USD/EUR
(0.07%) $0.933
USD/NOK
(0.07%) $10.99
USD/GBP
(0.01%) $0.796
USD/RUB
(0.01%) $93.31

Echtzeitaktualisierungen für Hikma Pharmaceuticals PLC [HKMPY]

Börse: OTC Sektor: Healthcare Industrie: Drug Manufacturers—Specialty & Generic
Zuletzt aktualisiert15 Apr 2024 @ 16:33

0.00% $ 46.50

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:33):

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...

Stats
Tagesvolumen 123.00
Durchschnittsvolumen 130.00
Marktkapitalisierung 5.16B
Last Dividend $0.500 ( 2023-08-11 )
Next Dividend $0 ( N/A )
P/E 27.35
ATR14 $0 (0.00%)

Hikma Pharmaceuticals PLC Korrelation

10 Am meisten positiv korreliert
10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Hikma Pharmaceuticals PLC Finanzdaten

Annual 2023
Umsatz: $2.88B
Bruttogewinn: $1.39B (48.35 %)
EPS: $1.720
FY 2023
Umsatz: $2.88B
Bruttogewinn: $1.39B (48.35 %)
EPS: $1.720
FY 2022
Umsatz: $2.52B
Bruttogewinn: $1.24B (49.19 %)
EPS: $1.680
FY 2021
Umsatz: $2.55B
Bruttogewinn: $1.30B (50.96 %)
EPS: $3.57

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.380
(N/A)
$0
(N/A)
$0.740
(N/A)
$0
(N/A)
$0.500
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Hikma Pharmaceuticals PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.96 - Stable (0.75%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.150 2012-04-18
Last Dividend $0.500 2023-08-11
Next Dividend $0 N/A
Payout Date 2023-09-25
Next Payout Date N/A
# dividends 24 --
Total Paid Out $8.89 --
Avg. Dividend % Per Year 0.00% --
Score 3.65 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.96
Div. Directional Score 8.04 --
Next Divdend (Est)
(2024-06-21)
$0.505 Estimate 7.56 %
Dividend Stability
0.30 Poor
Dividend Score
3.65
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
NUBC Ex Dividend Knight 2023-09-07 Quarterly 0 0.00%
CZNL Ex Dividend Knight 2023-09-18 Quarterly 0 0.00%
TISCF Ex Dividend Junior 2023-09-28 Annually 0 0.00%
IKTSY Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
BHRB Ex Dividend Knight 2023-08-14 Quarterly 0 0.00%
PRNDY Ex Dividend Knight 2023-06-30 Semi-Annually 0 0.00%
EMSHF Ex Dividend Knight 2023-08-15 Annually 0 0.00%
UNCHF Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
KIROY Ex Dividend Knight 2023-08-17 Semi-Annually 0 0.00%
CCFN Ex Dividend Knight 2023-08-14 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06621.5008.6810.00[0 - 0.5]
returnOnAssetsTTM0.04051.2008.6510.00[0 - 0.3]
returnOnEquityTTM0.08641.500-0.151-0.227[0.1 - 1]
payoutRatioTTM0.723-1.0002.77-2.77[0 - 1]
currentRatioTTM1.5680.8007.165.73[1 - 3]
quickRatioTTM0.8900.8009.477.58[0.8 - 2.5]
cashRatioTTM0.1531.500-0.261-0.391[0.2 - 2]
debtRatioTTM0.254-1.5005.76-8.64[0 - 0.6]
interestCoverageTTM5.461.0009.099.09[3 - 30]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
freeCashFlowPerShareTTM2.962.008.5210.00[0 - 20]
debtEquityRatioTTM0.542-1.5007.83-10.00[0 - 2.5]
grossProfitMarginTTM0.4591.0005.695.69[0.2 - 0.8]
operatingProfitMarginTTM0.1651.0008.708.70[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4441.0008.648.64[0.2 - 2]
assetTurnoverTTM0.6120.8009.257.40[0.5 - 2]
Total Score11.11

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM27.061.0007.370[1 - 100]
returnOnEquityTTM0.08642.50-0.0971-0.227[0.1 - 1.5]
freeCashFlowPerShareTTM2.962.009.0110.00[0 - 30]
dividendYielPercentageTTM3.051.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
payoutRatioTTM0.7231.5002.77-2.77[0 - 1]
pegRatioTTM1.9541.5000.3060[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1851.0007.880[0.1 - 0.5]
Total Score4.96

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.